TLRY - Tilray, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Leamington,
Canada
Type: Equity
TLRY price evolution
TLRY
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $228.34 | $146.25 | ||
| Short term investments | $32.18 | $79.61 | ||
| Net receivables | $104.04 | $101.69 | $89.54 | |
| Inventory | $264.3 | $252.09 | $244.14 | |
| Total current assets | $725.88 | $677.71 | $631.21 | |
| Long term investments | $39.86 | $40.06 | ||
| Property, plant & equipment | $572.31 | $574.35 | $596.24 | |
| Goodwill & intangible assets | $2924.35 | $2939.74 | ||
| Total noncurrent assets | $3543.95 | $3581.64 | ||
| Total investments | $72.04 | $119.66 | ||
| Total assets | $4261.87 | $4221.66 | $4212.86 | |
| Current liabilities | ||||
| Accounts payable | $101.87 | $241.96 | $209.76 | |
| Deferred revenue | ||||
| Short long term debt | $38.96 | $116.16 | ||
| Total current liabilities | $293.55 | $299.17 | $329.1 | |
| Long term debt | $331.65 | $348.36 | $365.46 | |
| Total noncurrent liabilities | $479.32 | $540.72 | ||
| Total debt | $387.32 | $481.62 | ||
| Total liabilities | $783.78 | $778.49 | $869.82 | |
| Shareholders' equity | ||||
| Retained earnings | -$2699.65 | -$2660.49 | -$2628.74 | |
| Other shareholder equity | -$39.88 | -$43.5 | -$43.19 | |
| Total shareholder equity | $3442.91 | $3358.86 | ||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $228.34 | $206.63 | $415.91 | $488.47 |
| Short term investments | $32.18 | $241.9 | $2.48 | |
| Net receivables | $101.69 | $86.23 | $95.28 | $87.31 |
| Inventory | $252.09 | $200.55 | $245.53 | $256.43 |
| Total current assets | $677.71 | $773.03 | $803.5 | $883.61 |
| Long term investments | $39.86 | $115.77 | $126.2 | $17.68 |
| Property, plant & equipment | $574.35 | $435.61 | $600.5 | $668.97 |
| Goodwill & intangible assets | $2924.35 | $2982.63 | $3919.18 | $4438.71 |
| Total noncurrent assets | $3543.95 | $3534.23 | $4646.19 | $5141.75 |
| Total investments | $72.04 | $357.67 | $126.2 | $20.17 |
| Total assets | $4221.66 | $4307.26 | $5449.69 | $6025.36 |
| Current liabilities | ||||
| Accounts payable | $241.96 | $190.68 | $157.43 | $212.81 |
| Deferred revenue | ||||
| Short long term debt | $38.96 | $224.26 | $92.65 | $49.6 |
| Total current liabilities | $299.17 | $432.98 | $280.34 | $401.24 |
| Long term debt | $348.36 | $365.87 | $531.16 | $889.06 |
| Total noncurrent liabilities | $479.32 | $544.34 | $727.99 | $1158.81 |
| Total debt | $387.32 | $590.13 | $623.81 | $938.66 |
| Total liabilities | $778.49 | $977.32 | $1008.33 | $1560.05 |
| Shareholders' equity | ||||
| Retained earnings | -$2660.49 | -$2415.51 | -$962.85 | -$486.05 |
| Other shareholder equity | -$43.5 | -$46.61 | -$20.76 | $152.67 |
| Total shareholder equity | $3442.91 | $3315.69 | $4398.81 | $4459.07 |
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $229.88 | $188.34 | ||
| Cost of revenue | $147.53 | $138.94 | ||
| Gross Profit | $82.35 | $49.4 | ||
| Operating activities | ||||
| Research & development | $0.39 | $0.11 | ||
| Selling, general & administrative | $69.38 | $61.13 | ||
| Total operating expenses | $97.88 | $137.48 | ||
| Operating income | -$15.53 | -$88.08 | ||
| Income from continuing operations | ||||
| EBIT | -$49.92 | -$87.06 | ||
| Income tax expense | -$27.63 | -$2.87 | ||
| Interest expense | $9.46 | $8.52 | ||
| Net income | ||||
| Net income | -$31.75 | -$92.7 | ||
| Income (for common shares) | -$31.75 | -$92.7 | ||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $788.94 | $627.12 | $628.37 | $513.09 |
| Cost of revenue | $565.59 | $480.16 | $511.56 | $389.9 |
| Gross Profit | $223.35 | $146.96 | $116.82 | $123.18 |
| Operating activities | ||||
| Research & development | $0.64 | $0.68 | $1.52 | $0.83 |
| Selling, general & administrative | $246.52 | $230.94 | $228.66 | $155.69 |
| Total operating expenses | $413.89 | $1515.79 | $771.87 | $255.35 |
| Operating income | -$190.53 | -$1368.83 | -$655.05 | -$132.17 |
| Income from continuing operations | ||||
| EBIT | -$235.16 | -$1446.25 | -$455.4 | -$348.42 |
| Income tax expense | -$26.62 | -$7.18 | -$6.54 | -$8.97 |
| Interest expense | $36.43 | $13.59 | $27.94 | $27.98 |
| Net income | ||||
| Net income | -$244.98 | -$1452.66 | -$476.8 | -$367.42 |
| Income (for common shares) | -$244.98 | -$1452.66 | -$476.8 | -$367.42 |
| (in millions $) | 1 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$31.75 | -$92.7 | -$49.01 | |
| Operating activities | ||||
| Depreciation | $31.73 | $32.84 | $31.55 | |
| Business acquisitions & disposals | -$83.58 | |||
| Stock-based compensation | $7.25 | $8.06 | $8.2 | |
| Total cash flows from operations | $30.71 | -$15.36 | -$30.41 | |
| Investing activities | ||||
| Capital expenditures | -$2.37 | -$8.73 | -$5.84 | |
| Investments | $47.42 | $36.81 | $45.44 | |
| Total cash flows from investing | -$49.4 | $45.06 | $28.09 | $81.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.62 | |||
| Net borrowings | -$1.55 | -$10.91 | -$85.37 | |
| Total cash flows from financing | $60.59 | $7.07 | -$10.91 | -$85.37 |
| Effect of exchange rate | $0.96 | -$0.75 | -$0.51 | $0.1 |
| Change in cash and equivalents | -$23.15 | $82.09 | $1.3 | -$34.18 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$244.98 | -$1452.66 | -$476.8 | -$367.42 |
| Operating activities | ||||
| Depreciation | $126.91 | $130.15 | $154.59 | $67.83 |
| Business acquisitions & disposals | -$60.63 | -$26.72 | $0.33 | $75.04 |
| Stock-based compensation | $31.77 | $39.59 | $35.99 | $17.35 |
| Total cash flows from operations | -$30.91 | $7.91 | -$177.26 | -$44.72 |
| Investing activities | ||||
| Capital expenditures | -$20.74 | -$16.5 | -$21.86 | -$32.27 |
| Investments | $209.72 | -$241.9 | $3.33 | |
| Total cash flows from investing | $128.35 | -$285.11 | -$21.53 | $46.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.62 | $128.4 | $259.23 | $102.69 |
| Net borrowings | -$83.81 | -$58.25 | -$123.55 | $45.51 |
| Total cash flows from financing | -$75.19 | $70.16 | $128.2 | $124.31 |
| Effect of exchange rate | -$0.55 | -$2.23 | -$1.96 | $2.12 |
| Change in cash and equivalents | $21.71 | -$209.28 | -$72.56 | $127.82 |
News
|
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for...
Zacks · via Yahoo Finance
21 Feb 2025
|
|
Is Tilray Brands, Inc. (TLRY) the Best Get Rich Fast Stock to Buy Now?
Insider Monkey · via Yahoo Finance
20 Feb 2025
|
|
Canada stocks higher at close of trade; S&P/TSX Composite up 0.65% By...
Investing.com
19 Feb 2025
|
|
Best Cannabis Stocks To Keep An Eye On – February 16th
ETF DAILY NEWS
19 Feb 2025
|
|
Top Cannabis Stocks To Watch Today – February 17th
ETF DAILY NEWS
19 Feb 2025
|
|
Tilray Brands, Inc. (TLRY): Among the Best Alcohol Stocks to Buy According to...
Insider Monkey · via Yahoo Finance
2 Feb 2025
|
|
Equities Analysts Issue Forecasts for Tilray FY2025 Earnings
ETF DAILY NEWS
17 Jan 2025
|
|
Pallas Capital Advisors LLC Has $67,000 Stake in Tilray Inc (NASDAQ:TLRY)
ETF DAILY NEWS
16 Jan 2025
|
|
Canaccord Genuity Group Increases Tilray (NASDAQ:TLRY) Price Target to $3.00
ETF DAILY NEWS
15 Jan 2025
|
|
Tilray (NASDAQ:TLRY) Shares Down 4.1% After Earnings Miss
ETF DAILY NEWS
15 Jan 2025
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |